Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-006906-58
    Sponsor's Protocol Code Number:PHA022121-C303
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-05-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-006906-58
    A.3Full title of the trial
    A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II).
    Studio di estensione di fase II/III del farmaco PHA-022121 somministrato per via orale per il trattamento acuto degli attacchi da angioedema in pazienti affetti da angioedema ereditario dovuto a deficit del C1 inibitore (tipo I o tipo II).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema.
    Studio di estensione di fase 2/3 per testare la sicurezza a lungo termine della somministrazione orale di PHA-022121 per il trattamento acuto degli attacchi di angioedema in pazienti con angioedema ereditario.
    A.3.2Name or abbreviated title of the trial where available
    RAPIDe-2
    RAPIDe-2
    A.4.1Sponsor's protocol code numberPHA022121-C303
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPharvaris Netherlands B.V.
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPharvaris Netherlands BV
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPharvaris Netherlands BV
    B.5.2Functional name of contact pointPharvaris Clinical
    B.5.3 Address:
    B.5.3.1Street AddressJ.H. Oortweg 21
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 CH
    B.5.3.4CountryNetherlands
    B.5.5Fax number+31712036410
    B.5.6E-mailclinical@pharvaris.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePHVS416
    D.3.2Product code [PHA-022121]
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNA
    D.3.9.1CAS number 2340111-58-0
    D.3.9.2Current sponsor codePHA-022121
    D.3.9.3Other descriptive namePHA-022121
    D.3.9.4EV Substance CodeSUB206489
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Firazyr 30 mg solution for injection in pre-filled syringe
    D.2.1.1.2Name of the Marketing Authorisation holderShire Pharmaceuticals Ireland Limited
    D.2.1.2Country which granted the Marketing AuthorisationIreland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFirazyr
    D.3.2Product code [Firazyr]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIcatibant
    D.3.9.1CAS number 138614-30-9
    D.3.9.2Current sponsor codeFirazyr
    D.3.9.4EV Substance CodeSUB29718
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, soft
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hereditary angioedema attacks caused by Type 1 and 2 C1-Inhibitor Deficiency
    Attacchi di angioedema ereditario causati dall'inibitore C1 di tipo 1 e 2 Carenza
    E.1.1.1Medical condition in easily understood language
    Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling
    L'angioedema ereditario (HAE) è un disturbo che provoca recidive attacchi di forte gonfiore
    E.1.1.2Therapeutic area Body processes [G] - Immune system processes [G12]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level PT
    E.1.2Classification code 10019860
    E.1.2Term Hereditary angioedema
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10080956
    E.1.2Term Hereditary angioedema type I
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10080957
    E.1.2Term Hereditary angioedema C1 inhibitor deficiency
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 24.0
    E.1.2Level LLT
    E.1.2Classification code 10080960
    E.1.2Term Hereditary angioedema type II
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety of long-term on-demand treatment with PHA-022121 for acute hereditary angioedema (HAE) attacks including laryngeal attacks.
    Per valutare la sicurezza del trattamento a richiesta a lungo termine con PHA-022121 per gli attacchi di angioedema ereditario acuto (HAE), inclusi gli attacchi laringei.
    E.2.2Secondary objectives of the trial
    • To evaluate the efficacy of PHA-022121 in achieving symptom relief in patients with acute HAE attacks including laryngeal attacks,
    • To evaluate the maintenance of PHA-022121 efficacy in achieving symptom relief for any subsequent acute HAE attacks including laryngeal attacks,
    • To evaluate the proportion of PHA-022121-treated attacks requiring a second dose of PHA-022121 to achieve symptom relief.
    • Per valutare l'efficacia di PHA-022121 nel raggiungimento del sollievo dai sintomi in pazienti con attacchi di HAE acuti, inclusi attacchi laringei,
    • Per valutare il mantenimento dell'efficacia del PHA-022121 nel raggiungimento del sollievo dai sintomi per qualsiasi successivo attacco acuto di HAE, inclusi attacchi laringei,
    • Valutare la proporzione di attacchi trattati con PHA-022121 che richiedono una seconda dose di PHA-022121 per ottenere un sollievo dai sintomi.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Provision of written informed consent.
    2. Male or female, aged = 18 years at the time of providing written informed consent.
    3. Patients must have received at least 1 dose of study drug (including the non-attack visit) in Study PHA022121-C201.
    4. Female patients of childbearing potential must agree to the protocol specified pregnancy testing and to be abstinent from heterosexual intercourse or to use an acceptable form of contraception methods from enrollment until 30 days after the last study drug administration. Methods acceptable for this study include male condom with or without spermicide, cervical cap, diaphragm or sponge with spermicide, a combination of male condom with cap, diaphragm or sponge with spermicide (double-barrier methods), progestin-only hormonal methods (oral, injectable, or implantable), intrauterine device (IUD, all types),intrauterine hormone releasing systems (IUS).Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal (defined as no menses for at least 12 months without an alternative medical cause and a follicle-stimulating hormone (FSH) test result indicative of post-menopausal status) do not require contraception during the study. There are no contraceptiverequirements for male patients.
    5. In the opinion of the investigator is willing and able to comply with the protocol.
    1. Fornitura del consenso informato scritto.
    2. Uomo o donna, di età = 18 anni al momento della prestazione del consenso informato scritto.
    3. I pazienti devono aver ricevuto almeno 1 dose del farmaco in studio (compresa la visita senza attacco) nello Studio PHA022121-C201.
    4. Le pazienti di sesso femminile in età fertile devono accettare il test di gravidanza specificato dal protocollo e astenersi dai rapporti eterosessuali o utilizzare una forma accettabile di metodi contraccettivi dall'arruolamento fino a 30 giorni dopo l'ultima somministrazione del farmaco in studio. I metodi accettabili per questo studio includono preservativo maschile con o senza spermicida, cappuccio cervicale, diaframma o spugna con spermicida, una combinazione di preservativo maschile con cappuccio, diaframma o spugna con spermicida (metodi a doppia barriera), metodi ormonali a base di solo progestinico (orale, iniettabile o impiantabile), dispositivo intrauterino (IUD, tutti i tipi), sistemi intrauterini di rilascio di ormoni (IUS). Donne in età non fertile, definite chirurgicamente sterili (stato post-isterectomia, ovariectomia bilaterale o legatura delle tube bilaterale) o post- la menopausa (definita come assenza di mestruazioni per almeno 12 mesi senza una causa medica alternativa e un risultato del test dell'ormone follicolo-stimolante (FSH) indicativo dello stato post-menopausale) non richiede contraccezione durante lo studio. Non ci sono requisiti contraccettivi per i pazienti di sesso maschile.
    5. A giudizio dello sperimentatore è disposto e in grado di rispettare il protocollo
    E.4Principal exclusion criteria
    1. Any female who is pregnant or is breast-feeding.
    2. Presence of any medical condition that could interfere with the assessment of safety or efficacy or negatively affect the patient's safety, including clinically significant abnormal ECG, most notably a QTcF > 470 ms (for females) or > 450 ms (for males), cardiovascular disease, abnormal liver function and abnormal kidney function.
    3. Any other systemic disease (e.g., gastrointestinal, renal, respiratory,neurological) or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study.
    4. Use of lanadelumab for long-term HAE prophylactic therapy within 12 weeks prior to study enrollment. Patients who have recently used short or long-term HAE prophylaxis or on-demand HAE treatment will not be excluded from the study provided the following washout period is observed (i.e., study screening or enrollment should be delayed allowing for washout):
    • 2-week washout period before enrollment should be respected for patients who have used any C1-INH product, oral kallikrein inhibitors,attenuated androgens, or anti-fibrinolytics for long-term prophylactic
    HAE therapy.
    • 1-week washout period before enrollment should be respected for patients who have used plasma derived C1-INH concentrates (Berinert,Cinryze, Haegarda) for on-demand treatment or short-term prophylaxis.
    • 24-hour washout period before enrollment should be respected for patients who have used recombinant C1-INH (Ruconest) for on-demand treatment or short-term prophylaxis.
    6. History of alcohol or drug abuse within the previous year, or current evidence of substance dependence or abuse.
    7. Discontinued from Study PHA022121-C201 after enrollment for any study drug-related safety reason.
    8. Participation in any other investigational drug study (except with PHA-022121) currently, within the last 30 days prior to the first PHA-022121 dose or within 5 half-lives of study drug at enrollment,whichever is longer.
    9. Use of concomitant medications that are potent CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir, grapefruit) or potent CYP3A4 inducers (e.g., phenytoin,rifampicin, St. John's Wort).
    1. Qualsiasi donna incinta o che allatta al seno.
    2. Presenza di qualsiasi condizione medica che potrebbe interferire con la valutazione della sicurezza o dell'efficacia o influenzare negativamente la sicurezza del paziente, compreso un ECG anormale clinicamente significativo, in particolare un QTcF > 470 ms (per le femmine) o > 450 ms (per i maschi), malattie cardiovascolari, funzionalità epatica anormale e funzionalità renale anormale.
    3. Qualsiasi altra malattia sistemica (ad es. gastrointestinale, renale, respiratoria, neurologica) o malattia o disturbo significativo che potrebbe interferire con la sicurezza o la capacità del paziente di partecipare allo studio.
    4. Uso di lanadelumab per la terapia profilattica di HAE a lungo termine entro 12 settimane prima dell'iscrizione allo studio. I pazienti che hanno utilizzato di recente una profilassi per l'HAE a breve o lungo termine o un trattamento on-demand per l'HAE non saranno esclusi dallo studio a condizione che si osservi il seguente periodo di washout (ovvero, lo screening dello studio o l'arruolamento devono essere ritardati tenendo conto del washout):
    • Il periodo di sospensione di 2 settimane prima dell'arruolamento deve essere rispettato per i pazienti che hanno utilizzato qualsiasi prodotto C1-INH, inibitori orali della callicreina, androgeni attenuati o antifibrinolitici per profilassi a lungo termine
    Terapia dell'HAE.
    • Il periodo di sospensione di 1 settimana prima dell'arruolamento deve essere rispettato per i pazienti che hanno utilizzato concentrati di C1-INH derivati ¿¿dal plasma (Berinert, Cinryze, Haegarda) per il trattamento su richiesta o la profilassi a breve termine.
    • Il periodo di washout di 24 ore prima dell'arruolamento deve essere rispettato per i pazienti che hanno utilizzato C1-INH ricombinante (Ruconest) per il trattamento su richiesta o la profilassi a breve termine.
    6. Storia di abuso di alcol o droghe nell'anno precedente, o prove attuali di dipendenza o abuso di sostanze.
    7. Interrotto dallo studio PHA022121-C201 dopo l'arruolamento per qualsiasi motivo di sicurezza correlato al farmaco in studio.
    8. Partecipazione a qualsiasi altro studio sperimentale sul farmaco (tranne con PHA-022121) attualmente, negli ultimi 30 giorni prima della prima dose di PHA-022121 o entro 5 emivite del farmaco in studio al momento dell'arruolamento, a seconda di quale sia il periodo più lungo.
    9. Uso di farmaci concomitanti che sono potenti inibitori del CYP3A4 (ad es. claritromicina, eritromicina, itraconazolo, ketoconazolo, ritonavir, pompelmo) o potenti induttori del CYP3A4 (ad es. fenitoina, rifampicina, erba di San Giovanni).
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoints of the study are
    •TEAEs, treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), and treatment-related TESAEs
    • Clinical laboratory tests
    • Vital signs
    Gli endpoint primari dello studio sono
    •TEAE, TEAE correlati al trattamento, eventi avversi gravi emergenti dal trattamento (TESAE) e TESAE correlati al trattamento
    • Test clinici di laboratorio
    • Segni vitali
    E.5.1.1Timepoint(s) of evaluation of this end point
    • TEAES will be evaluated when taking place
    • Clinical laboratory tests will be evaluated as follows:
    Part A: at Screening visit and every 3 months
    Part B: when patients transition to Part B, then every 3 months for the first 6 months, and every 6 months thereafter and 14 to 28 days after the last treatment administration
    • Vital signs
    Part A: at Screening visit and every 3 months
    Part B: when patients transition to Part B, then every 3 months for the first 6 months, and every 6 months thereafte
    • I TEAES saranno valutati al momento dello svolgimento
    • I test clinici di laboratorio saranno valutati come segue:
    Parte A: alla visita di screening e ogni 3 mesi
    Parte B: quando i pazienti passano alla Parte B, quindi ogni 3 mesi per i primi 6 mesi e successivamente ogni 6 mesi e da 14 a 28 giorni dopo l'ultima somministrazione del trattamento
    • Segni vitali
    Parte A: alla visita di screening e ogni 3 mesi
    Parte B: quando i pazienti passano alla Parte B, poi ogni 3 mesi per i primi 6 mesi e successivamente ogni 6 mesi
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    differente dosaggio dello stesso prodotto
    Different dosage of the same product
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA13
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Israel
    United States
    France
    Poland
    Bulgaria
    Spain
    Czechia
    Germany
    Italy
    Hungary
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The End-of-Study visit is to occur between 14 to 28 days after the last treatment administration and if possible in case of withdrawal from the study.
    La visita di fine studio deve avvenire tra 14 e 28 giorni dopo l'ultima somministrazione del trattamento e se possibile in caso di recesso dal studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 54
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 18
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state1
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 48
    F.4.2.2In the whole clinical trial 72
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The study is planned to continue until the availability of commercial supply, or another means of continued treatment can be provided
    Si prevede che lo studio proseguirà fino alla disponibilità della fornitura commerciale o fino a quando non sarà possibile fornire un altro mezzo per continuare il trattamento
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-07-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-04-12
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Apr 29 20:00:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA